5 results about "Treprostinil" patented technology

This disclosure provides a dry powder composition of treprostol prodrug and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension or PH associated with interstitial lung disease) in patients in need using said dry powder composition. The dry powder composition comprises: (a) about 0.5 wt% to about 5 wt% of a compound, its stereoisomers, or a pharmaceutically acceptable salt thereof; (b) about 10 wt% to about 61 wt% of leucine; and the remainder is (c) a sugar selected from the group consisting of trehalose and mannitol. The total of (a), (b), and (c) is 100 wt%, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecanyl, or octadecyl. The method of treating PH comprises administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler during an administration period.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure relates to the treatment of diseases, such as pulmonary hypertension, by inhalation of a combination of iloprost and treprostinil.

Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.

A combination therapy for treating pulmonary hypertension (e.g., PAH, PH-ILD) includes a dose of treprostinil comprising greater than 10 micrograms of treprostinil and a dose of an ActRIIA fusion protein. The dose of treprostinil and the dose of ActRIIA fusion protein may be administered concurrently or sequentially. Further methods for treating pulmonary hypertension include administering a therapeutically effective amount of ActRIIA fusion protein to a subject who has received a composition containing treprostinil, or administering a composition containing treprostinil to a subject who has received a therapeutically effective amount of ActRIIA fusion protein. The treprostinil may be administered as a dry7 powder or liposomal composition.